Investors who lost money in SLNO after its stock plunged due to allegedly misleading financial statements are urged to contact…
NEW YORK and NEW ORLEANS, April 14, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss…
SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and…
Das Übernahme-Karussell im Biotech-Sektor dreht sich gefühlt von Woche zu Woche immer schneller. Erst am Ostermontag hat Neurocrine Biosciences die…
Das Übernahme-Karussell im Biotech-Sektor dreht sich gefühlt von Woche zu Woche immer schneller. Erst am Ostermontag hat Neurocrine Biosciences die…
Investors need to pay close attention to SLNO stock based on the movements in the options market lately.…
…
Neurocrine ?Biosciences will acquire rare disease drugmaker ?Soleno Therapeutics for $2.9 billion in cash, the companies said ?on ?Monday.…
Neurocrine Biosciences (NASDAQ:NBIX) has agreed to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash transaction valued at approximately $2.9...…
Notice to Long-Term Shareholders of ASP Isotopes (NASDAQ: ASPI); Camping World (NYSE: CWH); EOS Energy (NASDAQ: EOSE); and Soleno (NASDAQ:…
The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.…
NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and…
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its…
…
Soleno Therapeutics tumbles despite Q3 earnings, revenue beat…
NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
Scorpion Capital alleged Soleno’s sole product, Vykat XR, was overpriced and unsafe for children, causing shares to drop 7.4% to…
Geschäftstreiber: Soleno Therapeutics (SLNO) hat sich auf die Entwicklung neuer Therapien und Medikamente für seltene Erkrankungen spezialisiert. Mit der FDA-Zulassung…
SLNO Investors with Losses Encouraged to Contact Hagens Berman SLNO Investors with Losses Encouraged to Contact Hagens Berman…
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
NEW YORK, Sept. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Lets find…
Geschäftstreiber: Soleno Therapeutics (SLNO) hat sich auf die Entwicklung neuer Therapien und Medikamente für seltene Erkrankungen spezialisiert. Mit der FDA-Zulassung…
Soleno Therapeutics stock falls after pricing $200 million offering…
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel…
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing…
Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research,…
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company…
Soleno ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika zur Behandlung seltener Krankheiten entwickelt. Mit der FDA-Zulassung von VYKAT XR,…
Soleno Therapeutics hat einen Meilenstein auf dem Markt für seltene Krankheiten erreicht. Die Behandlung mit Diazoxid-Cholin zielt darauf ab,…
…
…
…
The companys Prader-Willi treatment inched closer to FDA approval.…
REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
…
Soleno Therapeutics CFO sells over $298k in company stock…
REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi…
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a…
REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…